Analyzing GMAB Stock Performance – A Market Overview

By Tamara Parker • Wednesday, November 13 10:15 • Permanent Link

Genmab A/S logged a -1.6% change during today's morning session, and is now trading at a price of $22.1 per share. The S&P 500 index moved -0.0%. GMAB's trading volume is 291,380 compared to the stock's average volume of 894,412.

Genmab A/S trades -43.19% away from its average analyst target price of $38.9 per share. The 10 analysts following the stock have set target prices ranging from $25.0 to $51.0, and on average have given Genmab A/S a rating of buy.

Anyone interested in buying GMAB should be aware of the facts below:

Genmab A/S has moved -29.1% over the last year, and the S&P 500 logged a change of 32.9%
Based on its trailing earnings per share of 1.03, Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 21.5 while the S&P 500 average is 29.3
GMAB has a forward P/E ratio of 15.8 based on its forward 12 month price to earnings (EPS) of $1.4 per share
The company has a price to earnings growth (PEG) ratio of 0.79 — a number near or below 1 signifying that Genmab A/S is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 0.04 compared to its sector average of 3.53
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Based in Copenhagen, the company has 2,635 full time employees and a market cap of $14.44 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.